Metabolic Heterogeneity Underlying Hypertriglyceridemia: Hepatic Triglyceride Biosynthesis in Humans With Different Insulin Resistance Phenotypes

Recruiting now · Not applicable

Conditions studied: Insulin Resistance, Hypertriglyceridemia

In brief

The focus of this cross-sectional study is to determine the effects of tissue-specific (adipose tissue or muscle) vs global (combined) insulin resistance (IR) on hepatic triglyceride biosynthesis in humans, and to determine differential effects of an acute exercise intervention on hepatic triglyceride biosynthesis in these groups.

Key facts

Study ID

NCT05743868

Run by

Yale University

People needed

40

Starts

2023-11-16

Expected to finish

2026-06-01

Last updated by the study team

2026-01-27

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to give informed consent
• Overweight, defined as BMI 25-30 kg/m2
• Modest hypertriglyceridemia, defined as fasting plasma triglycerides 1.5-3.0mM
• High risk of insulin resistance, defined as fasting plasma insulin >64pM
• Stable weight for at least 3mo prior to participation

You may not qualify if…

• Active or chronic liver disease, kidney disease, congestive heart failure, unstable angina, history of acute cardiovascular events within 6mo of screening, history of seizures or syncope, or an active infection requiring antimicrobial therapy;
• Use of insulin, thiazolidinediones, SGLT2 inhibitors, or sulfonylureas;
• Use of fibrates, omega 3 (fish oil), niacin, or PCSK9 antagonists;
• Use of systemic glucocorticoids within 60d prior to participation;
• Hematocrit <35%;
• Pregnancy of breastfeeding;
• Active tobacco use, excessive alcohol intake (>14U/wk), or history of drug abuse.

Where it is running

• AMC Amsterdam — Amsterdam, Netherlands (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.